James Cs Chim
Professor of Haematology & Oncology
Department of Medicine
University of Hong Kong
Professor Chim has published 235 publications in international, peer-reviewed journals including Blood, Journal of Clinical Oncology, Leukemia. Moreover, he is the first and corresponding author in the majority (>150 publications). Besides, Prof Chim's international statue is illustrated by the followings. First, Prof Chim was awarded the National Scientific and Technological Advancement Award in 2009 (åå®¶ç§å¸æè¡é²æ¥ç). Secondly, Prof Chim was awarded the Fellowship of the Royal College of Pathologists (FRCPath)of UK, Fellowship of the Academy of Translational Medicine Professionals (FAcadTM), European Society for Translational Medicine (EUSTM) & Global Translational Medicine Consortium (GTMC) and Founding Fellowship of the Faculty of Science (FFSc), Royal College of Pathologist of Australia. Thirdly, Prof Chim was editorial board member of >60 journals including Carcinogenesis, PloS ONE and Bone Marrow Transplantation. Fourthly, Prof Chim was Advisory Board member of the International Myeloma Working Group, consultant of the American College of Physicians for Physicians’ Information and Education Resources (PIER), and Chairman of Education Program, Asia Pacific Hematology Consortium (APHCON). Moreover, Prof Chim was invited to serve as an international reviewer for the American Society of Hematology (ASH) annual meeting (one of an international panel of six comprising 2 from Dana Faber Cancer Institute of Harvard University, one from Cornell University, and 2 from Walter Eliza Institute from Australia), external reviewer for major overseas grant applications from Leukemia Research, Leukemia & Lymphoma Research, Cancer Research of United Kingdom, Czech Science Foundation, Association for International Cancer Research (AICR) and Agency for Science, Technology and Research (A*STAR). Furthermore, he has also been international reviewer for promotion of Associate Professor to tenure FULL Professor at the National University of Singapore, an external examiner for PhD students of the National University of Singapore, and external assessor for candidates of “Distinguished Researcher" and “Professor” to Shanghai Jiao Tong and HuaZhong Universities in addition to frequent invitations to review manuscripts for multiple reputable international journals including Blood and Leukemia. Prof Chim has been invited to lecture in post-ASH conference in New York, the Japanese Society of Medical Oncology (JSMO) in Osaka, Bridging the Gap meeting, organized by the MD Anderson Cancer Center in Singapore & Taiwan, & International Society of Hematology meeting in Beijing. He is also the Director for training of Haematology & Haematological Oncology, Hong Kong College of Physicians. Besides, he is the Visiting/Honorary Professor of 7 Medical Universities in mainland China including the Soozhou University, Shantong University, Peking University, People’s Liberation Army 301 Hospital (Beijing), Sun Yat-sen University (Guangzhou), and Tonji Medical School (Wuhan). Locally, Prof Chim is the Founding President of the Hong Kong Society of Myeloma, and has been the Chairman of the Hong Kong Society of Haematology. He has also served on the scientific committee of multiple international meetings. In addition, Prof Chim has also been awarded competitive RGC & NSFC grants since 2008, and two post-doc fellows. Currently, he is the principal supervisor of 4 PhD students, and has been the external examiner of National University of Singapore twice. Moreover, his dedication to teaching is also appreciated by the medical students. Last but not the least, Prof Chim is a conscientious clinician, and has won substantial appreciation from my patients and their relatives. Currently, my research focuses on “Epigenetic alterations in Blood Cancers”. Moreover, he is the Founding Chairman of the Society of Myeloma, which conducts territory-wide clinical studies in multiple myeloma. In summary, Prof Chim is both an experienced physician and clinician scientist, and is committed to translating scientific advances to quality patient care. Currently, he is a fellow of both the Royal Colleges of Physicians and Pathologists. Moreover, he is dually accredited in both Haematology and Medical Oncology by the Hong Kong College of Physicians.
Epigenetic alterations in Blood Cancers